The MARS-PE study is a retrospective observational study designed to evaluate clinical, echocardiographic, functional, and laboratory risk stratification markers in 182 patients with acute pulmonary embolism.
Observational (n=182)
No
The MARS-PE study is a retrospective cohort designed to evaluate the effectiveness of clinical, echocardiographic, functional, and laboratory markers for risk stratification in acute pulmonary embolism.
An acute pulmonary embolism (PE) is a crucial event in patients' life and connected with serious morbidity and mortality. Regarding a high case-fatality rate, early and accurate risk-stratification is crucial. Risk for mortality and complications are closely related to hemodynamic stability and cardiac adaptations. The currently recommended risk-stratification approach is not overall simple to use and might delay the identification of those patients, who should be monitored more closely and may treated with more aggressive treatment strategies. Additionally, some risk-stratification criteria for the imaging procedures are still imprecise. Summarized, the search for the most effective risk-stratification tools is still ongoing and some diagnostic criteria might have to be refined. In the MAinz Retrospective Study of Pulmonary Embolism (MARS-PE), overall 182 consecutive patients with confirmed PE were retrospectively included over a 5-year period. Clinical, echocardiographic, functional and laboratory parameters were assessed. The study was designed to provide answers to some of the mentioned relevant questions.
Keller et al. (Mon,) conducted a observational in Acute pulmonary embolism (n=182). Risk stratification markers was evaluated on All-cause in-hospital mortality, right ventricular dysfunction, myocardial injury, and PE severity status. The MARS-PE study is a retrospective observational study designed to evaluate clinical, echocardiographic, functional, and laboratory risk stratification markers in 182 patients with acute pulmonary embolism.